1. Home
  2. BEAM vs YELP Comparison

BEAM vs YELP Comparison

Compare BEAM & YELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BEAM
  • YELP
  • Stock Information
  • Founded
  • BEAM 2017
  • YELP 2004
  • Country
  • BEAM United States
  • YELP United States
  • Employees
  • BEAM N/A
  • YELP N/A
  • Industry
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • YELP Other Consumer Services
  • Sector
  • BEAM Health Care
  • YELP Consumer Discretionary
  • Exchange
  • BEAM Nasdaq
  • YELP Nasdaq
  • Market Cap
  • BEAM 1.7B
  • YELP 2.0B
  • IPO Year
  • BEAM 2020
  • YELP 2012
  • Fundamental
  • Price
  • BEAM $21.28
  • YELP $31.49
  • Analyst Decision
  • BEAM Strong Buy
  • YELP Hold
  • Analyst Count
  • BEAM 10
  • YELP 5
  • Target Price
  • BEAM $49.78
  • YELP $34.00
  • AVG Volume (30 Days)
  • BEAM 2.8M
  • YELP 815.6K
  • Earning Date
  • BEAM 11-04-2025
  • YELP 11-06-2025
  • Dividend Yield
  • BEAM N/A
  • YELP N/A
  • EPS Growth
  • BEAM N/A
  • YELP 16.67
  • EPS
  • BEAM N/A
  • YELP 2.19
  • Revenue
  • BEAM $60,272,000.00
  • YELP $1,451,224,000.00
  • Revenue This Year
  • BEAM N/A
  • YELP $6.30
  • Revenue Next Year
  • BEAM $18.20
  • YELP $4.20
  • P/E Ratio
  • BEAM N/A
  • YELP $14.44
  • Revenue Growth
  • BEAM N/A
  • YELP 5.37
  • 52 Week Low
  • BEAM $13.53
  • YELP $29.96
  • 52 Week High
  • BEAM $35.25
  • YELP $41.72
  • Technical
  • Relative Strength Index (RSI)
  • BEAM 62.79
  • YELP 45.93
  • Support Level
  • BEAM $19.57
  • YELP $30.87
  • Resistance Level
  • BEAM $21.59
  • YELP $31.74
  • Average True Range (ATR)
  • BEAM 1.24
  • YELP 0.61
  • MACD
  • BEAM 0.48
  • YELP 0.08
  • Stochastic Oscillator
  • BEAM 94.43
  • YELP 41.55

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About YELP Yelp Inc.

Yelp Inc operates in the online content market based in the United States. It provides a web-based platform and mobile application to bridge the gap between businesses and consumers. The platform assists consumers through product reviews, tips, photos and videos thereby enabling them in making better buying decisions and posting their feedbacks. Its products and services includes Advertising Products and Business Page Products. In addition, it also lets the buyers directly transact with businesses directly through its platform. Yelp generates revenue mainly from the sale of advertising on its website and mobile app to businesses. The company generates majority of the revenue from United States.

Share on Social Networks: